NCT01303965View on ClinicalTrials.gov

Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM)

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

February 7, 2011

Primary Completion Date

September 23, 2014

Study Completion Date

July 28, 2017

Conditions
Multiple Myeloma
Interventions
DRUG

Sirolimus

Start on Day -3 and continue for 1 year

DRUG

Tacrolimus

Start on Day -3 and begin tapering on Day +100 until Day +180.

DRUG

Lenalidomide

Start between Day +30 and +120 and continue for 1 year.

Trial Locations (1)

46202

Indiana University Melvin and Bren Simon Cancer Center, Indianapolis

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

Sherif S. Farag

OTHER

NCT01303965 - Allo Transplant Followed by Lenalidomide and Sirolimus Maintenance in High-Risk Multiple Myeloma (MM) | Biotech Hunter | Biotech Hunter